NEW YORK (GenomeWeb) – New England Biolabs and startup company CasZyme announced today that they have formed a multi-year collaboration to identify and commercialize CRISPR-Cas nucleases.

Under the terms of the agreement, the two companies will work to characterize new Cas nucleases using their expertise in enzymology, and NEB will then manufacture and commercially distribute the nucleases globally.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.